Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
05 December 1995Website:
http://www.novavax.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:56:44 GMTDividend
Analysts recommendations
Institutional Ownership
NVAX Latest News
Nvidia (NASDAQ: NVDA ) has become the face of artificial intelligence and its stock has responded in kind. Shares are up 200% over the past year and over 800% since the release of ChatGPT, which sparked an AI tsunami.
Novavax (NVAX) reachead $12.66 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.
Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax stock jumped this month as the company launched its updated Covid shot abroad. Is NVAX stock a buy or a sell right now?
In the most recent trading session, Novavax (NVAX) closed at $14.06, indicating a +1.99% shift from the previous trading day.
Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.
Novavax's stock is highly volatile due to the company's instability and inconsistent financial results. Sanofi has partnered with the company, and that has sparked a wave of excitement in Novavax's stock.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax, Inc. (NASDAQ:NVAX ) Jefferies 2024 Global Healthcare Conference June 6, 2024 12:30 PM ET Company Participants John Jacobs - President and CEO Filip Dubovsky - Chief Development Officer Jim Kelly - CFO Conference Call Participants Roger Song - Jefferies Roger Song All right. Good afternoon, everyone.
What type of business is Novavax?
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
What sector is Novavax in?
Novavax is in the Healthcare sector
What industry is Novavax in?
Novavax is in the Biotechnology industry
What country is Novavax from?
Novavax is headquartered in United States
When did Novavax go public?
Novavax initial public offering (IPO) was on 05 December 1995
What is Novavax website?
https://www.novavax.com
Is Novavax in the S&P 500?
No, Novavax is not included in the S&P 500 index
Is Novavax in the NASDAQ 100?
No, Novavax is not included in the NASDAQ 100 index
Is Novavax in the Dow Jones?
No, Novavax is not included in the Dow Jones index
When does Novavax report earnings?
The next expected earnings date for Novavax is 08 August 2024